South Korea Next-Generation Sequencing Market
South Korea Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing (Consumables), Platforms, Bioinformatics), Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The South Korea next-generation sequencing market is expected to reach USD 386.3 million by 2031, up from USD 201.0 million in 2026, at a CAGR of 14.0% from 2026 to 2031. Next-generation sequencing refers to advanced sequencing technologies that enable fast and comprehensive analysis of genetic material. These technologies are designed to efficiently decode DNA and RNA sequences and can be used in applications such as diagnostics, drug discovery, precision medicine, and genomic research.
KEY TAKEAWAYS
-
By CountrySouth Korea is experiencing robust growth in the next-generation sequencing market, driven by government-led initiatives and substantial funding commitments.
-
By OfferingBy offering, the products segment is projected to register steady growth, at a CAGR of 12.2% during the forecast period, with consumables, platforms, and bioinformatics tools showing consistent demand.
-
By ApplicationBy application, the diagnostics segment is projected to register a CAGR of 14.4% in the South Korea next-generation sequencing market during the forecast period.
-
Competitive Landscape - Star PlayersIllumina, Inc., Thermo Fisher Scientific Inc., and Qiagen were identified as leading players in the South Korea next-generation sequencing market, given their strong market presence and comprehensive product portfolios.
-
Competitive Landscape - StartupsOxford Nanopore Technologies plc. and Celemics have distinguished themselves among emerging players by introducing competitive innovations in sequencing technologies, underscoring their potential as growing market participants.
The South Korea Next-generation sequencing market is expanding rapidly, driven by the increasing demand for precision medicine, bespoke treatments, and genomic analysis projects. The South Korean government announced that it aims to give full support to the local biotechnology industry to raise the sector's production capacity to KRW 100 trillion (~USD 76.9 billion) by 2030 as part of its plans to become the world-leading biotech economy. This, in turn is expected to accelerate the development of cutting-edge NGS platforms and data analysis tools. Collaborations with international technology partners and initiatives focused on cancer genomics and personalized healthcare are further driving demand for high-performance sequencing technologies across the country.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The South Korea next-generation sequencing market is currently experiencing a phase of innovation and rapid adoption. Healthcare systems, research institutions, and pharmaceutical companies in South Korea are witnessing advancements in sequencing technology development and regulatory support. This progress aligns with emerging trends in precision medicine, genomic analysis, and personalized treatment approaches. In South Korea, the use of advanced sequencing platforms, bioinformatics tools, and consumables is increasing among hospitals, clinical laboratories, and research centers. These technologies facilitate comprehensive genetic analysis, which promotes faster diagnosis, enables targeted therapies, and aligns with precision medicine and patient-centric care approaches. Government agencies and regulatory bodies are encouraging local research and development, the establishment of national genome libraries, and public-private partnerships. These initiatives help accelerate approval timelines and promote the adoption of clinically validated sequencing platforms tailored to the needs of the South Korean patient population.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Declining cost of sequencing and advancements in bioinformatics
-
Strategic government investments in genomic research and healthcare infrastructure
Level
-
Ethical concerns regarding genetic data and privacy issues
Level
-
Growing demand for precision medicine and personalized treatment approaches
Level
-
High initial setup costs for sequencing technologies and infrastructure
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Declining cost of sequencing and advancements in bioinformatics
The declining cost of sequencing technologies and continuous advancements in bioinformatics are making next-generation sequencing more accessible across South Korea. These developments are enabling broader adoption in clinical diagnostics, research institutions, and pharmaceutical companies, supporting the integration of genomic analysis into routine healthcare and drug development processes.
Restraint: Ethical concerns regarding genetic data and privacy issues
Ethical concerns regarding the handling, storage, and use of genetic data present challenges for the adoption of Next-generation sequencing in South Korea. Issues related to patient privacy, data security, and informed consent require careful regulatory oversight and robust data governance frameworks to ensure responsible use of genomic information.
Opportunity: Growing demand for precision medicine and personalized treatment approaches
The growing demand for precision medicine and personalized treatment approaches presents significant growth opportunities in South Korea. Next-generation sequencing technologies are increasingly utilized to identify genetic variations, guide targeted therapies, and support individualized treatment plans, aligning well with the country's focus on advanced healthcare delivery and improved patient outcomes.
Challenge: High initial setup costs for sequencing technologies and infrastructure
High initial setup costs for sequencing technologies and supporting infrastructure remain a key challenge for smaller laboratories and healthcare facilities in South Korea. Investments in equipment, trained personnel, and data management systems are necessary to establish and maintain reliable sequencing capabilities, which can limit widespread adoption in resource-constrained settings.
SOUTH KOREA NEXT-GENERATION SEQUENCING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Illumina was selected as the sequencing technology partner to the Macrogen Consortium for South Korea’s National Bio Big Data Project, supporting sequencing and analysis of Korean genomes for national-scale genomics and precision medicine applications. | Supports high-throughput genome sequencing at population scale | Strengthens national genomics infrastructure | Enables broader clinical research, disease prediction, and precision medicine development in South Korea |
 |
Agilent partnered with Theragen Bio in South Korea to advance bioinformatic solutions for cancer genomic profiling, combining Agilent’s cancer genomic profiling capabilities with Theragen Bio’s software and local genomics expertise | Improves localized cancer genomic analysis workflows | Supports precision oncology decision-making | Enhances NGS-based clinical interpretation capabilities for South Korean diagnostics and research settings |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The South Korea next-generation sequencing market is a collaborative ecosystem where technology providers, research institutions, pharmaceutical companies, clinical laboratories, and healthcare professionals work together to develop and implement sequencing solutions in the healthcare and research sectors. Companies in the region supply a variety of sequencing platforms, consumables, and bioinformatics tools. Contract research organizations, academic institutions, and government agencies support the preclinical and clinical research stages, as well as the scale-up process for genomic analysis projects. Ultimately, healthcare institutions and providers in South Korea utilize the developed sequencing technologies, benefiting from supportive government policies and strategic funding initiatives.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
South Korea Next-generation Sequencing Market, by Offering
The products segment dominated the market in 2025, with sequencing platforms, consumables, and bioinformatics tools forming the foundation of genomic analysis capabilities in South Korean laboratories and healthcare facilities. This is due to their essential role in enabling comprehensive genetic analysis, supporting both research and clinical applications.
South Korea Next-generation Sequencing Market, by Application
Diagnostics represented the largest segment of the South Korea next-generation sequencing market. The increasing need for accurate genetic testing and disease diagnosis has propelled this segment to the forefront in the country. Factors such as the rising prevalence of cancer, genetic disorders, and infectious diseases, as well as the push for precision medicine, are driving the demand for diagnostic sequencing applications in clinical settings.
REGION
South Korea ais a key growth market in the next-generation sequencing sector
South Korea is a key growth market for next-generation sequencing, driven by substantial government investment, expanding healthcare infrastructure, and increasing adoption of precision medicine. The demand for genomic analysis in oncology, rare diseases, and drug development is increasing, along with the establishment of national genome libraries and research collaborations. Additionally, significant investment in research & development for personalized healthcare, combined with a strong focus on technological innovation, is facilitating the swift integration of sequencing technologies from research laboratories to clinical practice.
SOUTH KOREA NEXT-GENERATION SEQUENCING MARKET: COMPANY EVALUATION MATRIX
Illumina, Inc., recognized as a leading player in the South Korea next-generation sequencing market, offers a comprehensive portfolio that includes sequencing platforms, consumables, and bioinformatics solutions for clinical and research applications. The company has established strong partnerships with South Korean government agencies and research institutions, supporting national genome projects and precision medicine initiatives. Another significant player in the South Korean market is Thermo Fisher Scientific Inc., identified as a prominent provider. The company is strengthening its position by offering advanced sequencing instruments, reagents, and data analysis tools for diagnostics, drug discovery, and translational research.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 186.47 Million |
| Market Forecast in 2031 (Value) | USD 386.3 Million |
| Growth Rate | 14.0% |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | USD Million |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Country Covered | South Korea |
WHAT IS IN IT FOR YOU: SOUTH KOREA NEXT-GENERATION SEQUENCING MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Market adoption assessment | Conducted a detailed assessment of NGS adoption across key healthcare and research institutions in South Korea |
|
| End user mapping | Mapped key end users including hospitals, clinical diagnostic laboratories, academic research institutes, and government-supported genomics centers |
|
RECENT DEVELOPMENTS
- December 2024 : llumina announced that the Macrogen Consortium won the tender for the Korean National Bio Big Data Project, and Illumina was selected to support sequencing and analysis of Korean genomes.
- April 2023 : Agilent collaborated with Theragen Bio in South Korea to enhance bioinformatics for cancer genomic profiling. Agilent stated that the partnership aims to improve localized analysis capabilities and speed up treatment decisions in precision oncology, which is directly relevant to clinical NGS adoption in Korea.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study on the south korea next-generation sequencing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the south korea next-generation sequencing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the south korea next-generation sequencing market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the south korea next-generation sequencing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the next-generation sequencing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the next-generation sequencing market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall next-generation sequencing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile the key players in the south korea next-generation sequencing market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the south korea next-generation sequencing market
- To benchmark players within the south korea next-generation sequencing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the South Korea Next-Generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Still Researching the
South Korea Next-Generation Sequencing Ecosystem?
See the competitors, opportunity evaluation, and growth signals shaping it - Instantly!
Generate 15+ consulting-grade strategic intelligence outputs - from competitor analysis to board-ready strategy decks, tailored to your South Korea Next-Generation Sequencing growth question.
Growth opportunities and latent adjacency in South Korea Next-Generation Sequencing Market